An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT03909295
- Locations
- 🇯🇵
Novartis Investigative Site, Shinagawa-ku, Tokyo, Japan
A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT03907878
- Locations
- 🇯🇵
Novartis Investigative Site, Hiroshima, Japan
AScalate: Treat-to-target in Axial Spondyloarthritis
- Conditions
- Axial Spondyloarthritis
- Interventions
- Biological: Secukinumab/Adalimumab-BiosimilarOther: Standard-of-care
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 304
- Registration Number
- NCT03906136
- Locations
- 🇩🇪
Novartis Investigative Site, Ulm, Germany
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 273
- Registration Number
- NCT03905525
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 13
- Registration Number
- NCT03896152
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
- Conditions
- Nasopharyngeal CarcinomaMicrosatellite Stable Colorectal CancerCarcinoma, Non-Small-Cell LungMelanomaTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 98
- Registration Number
- NCT03891953
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)
- Conditions
- Cardiovascular Disease and Lipoprotein(a)
- Interventions
- Diagnostic Test: Blood draw for Lp(a)
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 49001
- Registration Number
- NCT03887520
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
- Conditions
- B-Cell Acute Lymphoblastic Leukemia
- Interventions
- Biological: CTL019
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 121
- Registration Number
- NCT03876769
- Locations
- 🇺🇸
Dana Farber Cancer Institute Dept.of DFCI, Boston, Massachusetts, United States
🇺🇸Methodist Childrens Hospital ., San Antonio, Texas, United States
🇺🇸City of Hope National Medical, Duarte, California, United States
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Biological: Tisagenlecleucel
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT03876028
- Locations
- 🇺🇸
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT03874858
- Locations
- 🇮🇹
Novartis Investigative Site, Novara, Italy